Tenders/Recombinant human insulin-like growth factor-1 (mekasermin) preparation for administration in generally available low-volume, high-precision syringes: - vial/ampoule with a capacity of < 50 mg
Awarded🇵🇱PolandSupplies

Recombinant human insulin-like growth factor-1 (mekasermin) preparation for administration in generally available low-volume, high-precision syringes: - vial/ampoule with a capacity of < 50 mg

Auto-translated from Polish
Original title: Preparat rekombinowanego ludzkiego insulinopodobnego czynnika wzrostu - 1 (mekasermina) do podawania w ogólnie dostępnych strzykawkach o małej pojemności i dużej dokładności: - fiolka/ampułka o pojemności < 50 mg
Instytut "Pomnik - Centrum Zdrowia Dziecka"
Published: Oct 9, 2026
Updated: Oct 12, 2026
Source: TED - Tenders Electronic Daily (EU)

This tender has been awarded

Awarded to NEUCA S.A — €6,096,115

Browse open Health & Medical tenders in Poland

About This Opportunity

This is a supplies contract in the health and medical services sector. Located in Poland, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.

Description

Auto-translated from Polish
1.The total volume of the basic order is: 135,330 mg. 2. The Ordering Party reserves the right to increase the quantity of the subject of the order, but not more than 15% of the basic order, in the amount of 20,250 mg. 3. The Ordering Party anticipates a change in the volume of the subject of the order during the term of the contract, i.e., a reduction in the ordered volume is permitted - by 20% of the basic order volume, in the event of objective and justified needs, in particular changes in demand among patients - this change depends on the internal needs of direct recipients, which may arise during the execution of the order and is left solely to its discretion. The Contractor, by submitting an offer, acknowledges the possibility of various circumstances affecting changes in demand. 4. The offered drug is registered and reimbursed for the treatment of recombinant IGF-1 in patients with short stature due to severe primary IGF-1 deficiency. 5. The offered preparation must meet the conditions for use in the above-mentioned indication in patients covered by drug program B.20, "Treatment of short children with severe primary insulin-like growth factor 1 deficiency" with recombinant human insulin-like growth factor-1. 6. Pursuant to art. 255 point 3 of the Pzp Act, the Ordering Party may annul the public procurement procedure if the price or cost of the most advantageous offer or the offer with the lowest price for the basic order exceeds the amount that the Ordering Party intends to allocate for financing the order. 7. Pursuant to art. 256 of the Pzp Act, the Ordering Party may annul the procedure before the expiry of the deadline for submitting offers if circumstances arise that make further conduct of the procedure unjustified. 8. Pursuant to art. 257 of the Pzp Act. The Ordering Party anticipates the possibility of annulling the public procurement procedure if the funds intended for financing all or part of the order have not been granted to it. 9.The order must be executed in accordance with the requirements specified in the SWZ and the Draft Contract Provisions. A detailed description of the subject of the order is specified in the Terms of Reference (SWZ). Evidentiary documents: Pursuant to art. 105 and art. 106 Pzp. in order to confirm the compliance of the offered supplies with the requirements, characteristics or criteria specified in the description of the subject of the order or the criteria for evaluating offers or requirements related to the execution of the order, the Ordering Party requests the Contractors to submit the following documents: • A valid marketing authorization for the medicinal product in the Republic of Poland issued by the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, or • A valid marketing authorization for the medicinal product issued by the Council of the European Union or the European Commission. 2.2. In the event of failure to attach the evidentiary documents mentioned in point 2.1. to the offer, the Ordering Party, in accordance with art. 107 sec. 2 of the Pzp Act. anticipates the possibility of a single supplementation of the aforementioned evidentiary documents, within the deadline set by the Ordering Party. 2.3. The marketing authorization for the medicinal product must be valid and current on the day of submitting the offers. 2.4. The composition of the preparation and packaging must be consistent with the content of the documents referred to in point 2.1. 2.5. In the event that the validity of the document expires, the Contractor is obliged to provide the Ordering Party, along with the documents referred to in point 2.1., with an additional document declaring the timely submission of an application for extension of the validity of the marketing authorization for the medicinal product or, if obtained, a valid marketing authorization for the medicinal product. 2.6. The Contractor is obliged to inform the Ordering Party about the transfer of rights and obligations of the responsible entity to another entity,...

Data provenance

This notice is sourced from TED - Tenders Electronic Daily (EU) and was originally published on October 9, 2026. Last refreshed 37 days ago. Original language: Polish. BidsFactory mirrors official procurement notices and links back to the source for full legal text.

About Instytut "Pomnik - Centrum Zdrowia Dziecka"

Instytut "Pomnik - Centrum Zdrowia Dziecka" has issued 8 procurement notices on BidsFactory, including 1 currently open and 3 awarded contracts. Activity concentrates in Health & Medical. All notices are published for Poland. Notices are distributed via TED - Tenders Electronic Daily (EU). Most recent publication: November 12, 2026.

Instytut "Pomnik - Centrum Zdrowia Dziecka": buyer profile, tenders and awards

Frequently asked questions about this tender

How can I submit a bid?

Visit TED - Tenders Electronic Daily (EU) to access the full notice, required documents, and submission instructions provided by the contracting authority.

Is this tender still open?

No — the contract has already been awarded to NEUCA S.A. The award notice is archived on BidsFactory for transparency and market intelligence.

Who is the contracting authority?

This notice was issued by Instytut "Pomnik - Centrum Zdrowia Dziecka" in Poland. The authority is responsible for evaluating bids, awarding the contract, and managing performance.

What type of contract is this?

This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.

How much was the contract awarded for?

NEUCA S.A was awarded the contract for €6,096,115. The figure reflects the value disclosed by the contracting authority in the award notice.

Where will the contract be performed?

The contract is for delivery in Poland. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.

Find tenders like this automatically

Premium shows the full details of every tender like this one and alerts you instantly when a new one is published.

See plans

Sectors & Categories

Key Details

Contract Type
Supplies
Eligibility
Firms / Consortiums
Language
Polish

Source

ted
TED - Tenders Electronic Daily (EU)
Public Procurement

Contracting Authority

Instytut "Pomnik - Centrum Zdrowia Dziecka"
🇵🇱Poland